Regulatory Record: VIWIT PHARM

FDA action counts

Enforcement history

On 2026-06-11, Argus HQ recorded an FDA approval for VIWIT PHARM, rated "info" severity in Argus HQ's classification: VIWIT PHARM — ANDA approval: GADOBUTROL (unspecified). Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

Risk pattern analysis

Argus HQ analysis — not an FDA finding

This section is Argus HQ analysis, not an FDA finding. VIWIT PHARM has 1 FDA event on file. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Frequently asked questions

What is the most recent FDA action against VIWIT PHARM?

The most recent FDA event Argus HQ has on file for VIWIT PHARM is dated 2026-06-11, with a severity rating of "info" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Does Argus HQ track new FDA actions for VIWIT PHARM automatically?

Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to VIWIT PHARM is observed, this page's event count and history update automatically.

How many FDA actions does Argus HQ track for VIWIT PHARM?

1 total: 0 warning letters, 0 recalls, 1 approval record, and 0 Form 483 inspection citations.

What is the most recent FDA action on file for VIWIT PHARM?

June 11, 2026. Argus HQ ingests new FDA enforcement records daily.

Related enforcement actions

• VIWIT PHARM — ANDA approval: GADOBUTROL (unspecified) →

Compare with

• VIWIT PHARM vs Medline Industries, LP
• VIWIT PHARM vs ARROW INTERNATIONAL, LLC
• VIWIT PHARM vs Stryker Sustainability Solutions
• VIWIT PHARM vs Guardian Drug Co. Inc.
• VIWIT PHARM vs B BRAUN MEDICAL INC